Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)
Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2537
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2537). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)
This text presents data on the proportion of patients with relapse over time, comparing the placebo group with the duloxetine group. The time in days from randomization to relapse is shown using the Kaplan-Meier estimator method. The chart/chart is showing the number of patients experiencing relapse in each group at different time intervals.*
Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)
This chart provides information on the proportion of patients experiencing relapse over time, comparing the effects of a placebo with Duloxetine treatment. The data is presented in days from randomization to relapse using the Kaplan-Meier estimator method.*
Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)
This text mentions the percentage of patients who showed improvement with different doses of Duloxetine and a placebo in a pain management study. It specifically highlights the percentage improvement in pain from baseline. This information is likely to be relevant for healthcare professionals or individuals wanting to understand the effectiveness of these medications in managing pain.*
Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)
Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)
This text provides information on the percentage of patients improved after taking different doses of Duloxetine and Placebo. It also shows the percent improvement in pain from the baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo.*
Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)
This is not available as the text does not provide a coherent description.*
Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)
This is a chart showing the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome who achieved various levels of pain relief at week 12 in Study FM-4. The data compares patients treated with Duloxetine 60mg once daily to those treated with a placebo. The pain relief was measured using the Brief Pain Inventory - Modified short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30 mg once daily for 1 week and then titrated to 60 mg once daily for 12 weeks.*
Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)
This text provides information on the percentage of patients improved with a placebo and Duloxetine 60/120 mg once daily. It also includes a chart showing the percentage improvement in pain from baseline (BOCF).*
Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)
This text provides information on the percentage of patients improved with Duloxetine 60 mg compared to a placebo, with a 100% improvement shown. The chart displays the percent improvement in pain from baseline.*
Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)
This text provides information on the percentage of patients who have improved while taking either a placebo or duloxetine 60/120 mg once daily. The data includes a graph illustrating the percent improvement in pain from baseline.*
Label (Lbl713352537)
This text provides information about a capsule containing enteric-coated pellets of Duloxetine HCI, USP equivalent to 30 mg. The packaging includes warnings about keeping the medication out of reach of children, the potential for drowsiness, storage instructions, and dispensing details. It also advises against using the capsules if the seal is broken or missing. Additionally, there is a recommendation to scan the package insert QR code for dosing information and to dispense the Medication Guide to each patient. The medication is identified with NDC number 71335-2537-1 and is manufactured by Bryant Ranch Prepack, Inc. and repackaged by Lupin Limited.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
